SCHEMBL7873648

SCHEMBL7873648

CCc1c(C(=O)O)n(C)c2ccc(NC(=O)c3ccccc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.53
NGFR P08138 1/20 0.53
KMT2A Q03164 9/20 0.52
MEN1 O00255 7/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 5/20 0.48
KDM4E B2RXH2 3/20 0.47
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 4/20 0.46
GFER P55789 1/20 0.46
KCNK3 O14649 2/20 0.45
KCNK9 Q9NPC2 2/20 0.45
MAPK1 P28482 1/20 0.45
ELANE P08246 1/20 0.45
HCRTR1 O43613 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4727925 0.78 NPY5R (0.65) NTRK1NGFRKMT2AMEN1RAB9A
SCHEMBL2272671 0.76 MEN1 (0.62) KMT2AMEN1POLBKDM4EMAPT
SCHEMBL7722872 0.73 MAPT (0.75) KMT2AMEN1POLBRAB9AKDM4E
SCHEMBL7113951 0.72 NPC1 (0.53) NTRK1NGFRKMT2AMEN1POLB
SCHEMBL4077706 0.72 MAPT (0.55) KMT2AMEN1RAB9AKDM4EMAPT
SCHEMBL28211409 0.71 NTRK1 (0.56) NTRK1NGFRKMT2AMEN1POLB
SCHEMBL27400764 0.71 MCL1 (0.57) NTRK1NGFRKMT2AMEN1RAB9A
SCHEMBL10003879 0.70 BRPF1 (0.51) KMT2AMEN1RAB9AMAPTLMNA
SCHEMBL16295912 0.70 MAPT (0.61) KMT2AMEN1POLBRAB9AKDM4E
SCHEMBL28211430 0.70 NTRK1 (0.54) NTRK1NGFRKMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed